SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Memecoin on Cronos launched by the Cro Crow community

crow with knife

The crypto "crow with knife" ($CAW.X) is trending as the community rallies behind its fully community-driven nature and cross-chain functionality. Active discussions revolve around its organic growth, deflationary mechanisms, and potential listings on major exchanges. The project's unique branding and engaged community, known as "murders," are also key talking points.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is trending as investors react to earnings and forward guidance, with debates around whether AI-driven demand justifies the stock's recent surge. Community discussions revolve around gross margins, potential upgrades, and the possibility of a post-earnings pullback after a significant run-up in recent months. Some traders express disappointment in the initial after-hours movement, while others remain optimistic about the company's long-term prospects in the semiconductor industry.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

RGTI is trending as discussions revolve around its potential in the quantum computing sector, with some traders pointing to a recent analyst upgrade. The community is debating whether the stock is overvalued, citing its high market cap relative to revenue, while others highlight its technological advancements and partnerships. Overall, sentiment is mixed with bullish investors anticipating further gains while bearish traders foresee a significant correction.

Cipher Mining, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Mining Inc

CIFR is trending amid speculation of a potential deal with a major player like Oracle, with the community buzzing about SoftBank's existing investment in Cipher Mining potentially facilitating such a partnership. Community members are closely watching for official news, anticipating a significant surge if a deal is confirmed, while also managing expectations of a possible short-term dip if the rumors prove unfounded. The stock's performance is also drawing comparisons to others in the AI and data center space, like IREN, as investors assess its potential for growth.

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo Inc. is trending due to discussions around its valuation relative to its future potential in the nuclear energy sector, with some community members pointing out the high valuation given its lack of current revenue. The stock's recent groundbreaking on its first Aurora powerhouse is fueling optimism, while others highlight regulatory hurdles and potential insider selling. Options positioning suggests a bullish outlook, although some investors are wary of a potential correction.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is trending as investors discuss the potential impact of a recent purchase order and its implications for future revenue and partnerships. Community members are debating whether the order size justifies the current valuation and speculating on upcoming news, particularly from the CIOE conference. The discussion also involves the company's potential role in the AI sector, with some expressing impatience for further commercial progress.

WTF Opossum is a Meme token on solana Blockchain with utilities and tools for traders and token owners as well. Launched in July 2024. The project built a vote for exposure telegram bot with a leaderboard for tokens on multiple blockchains. The variety of tools contain the voting agent, contract scanner and market details checker. The $WTFO token itself was designed as a unique meme character. An opossum, the symbol of immortals. Just like opossums, WTFO is a surviver, focusing on it's utilities and the fun aspect of communities as being a real meme project.

WTF Opossum

WTF Opossum ($WTFO.X) is gaining attention as community members highlight its burn mechanics, utility, and dedicated development team. Discussions suggest a shift in sentiment towards a long-term investment, supported by its continued building and surprising the community. Some users are pointing to its potential, meme power and strong market positioning.

United States Antimony Corp. engages in the extraction, processing and sale of antimony, zeolite, silver, and gold products. It operates through the following segments: United States Antimony Operations, Mexican Antimony Operations, Precious Metals Recovery, and United States Zeolite Operations. The company was founded by John C. Lawrence in June 1968 and is headquartered in Thompson Falls, MT.

United States Antimony Corp.

United States Antimony Corp

UAMY is trending following news of a $245 million defense contract, with community members discussing the potential for a short squeeze given the high short interest and comparing it to $MP's contract run. Investors are also anticipating further catalysts, including a potential DOD grant, and speculating about the company's growth prospects and potential acquisitions. The community sentiment is largely bullish, focusing on UAMY's strategic importance in securing a domestic antimony supply.

Infinite Money Glitch ($IMG) is revolutionizing DeFi on Solana by leveraging the Token2022 program's advanced tax extension capabilities to create a truly innovative reward system for token holders.  At its core, $IMG implements a seamless 5% tax on all transactions - whether buying, selling, or transferring tokens. This tax is automatically collected and distributed to holders in SOL, creating a sustainable passive income stream for the community. 4.5% of the tax gets sent to holders, while .5% gets sent to an Infrastructure wallet to help with development, marketing and general infrastructure.  What sets $IMG apart is its implementation of Solana's Token2022 program, enabling automated and efficient reward distribution without relying on external smart contracts.

Infinite Money Glitch

IMG.X is trending as the community rallies around recent developments, including a new partnership and upcoming fight sponsorship. The coin's reward system, which pays holders in Solana, is a key talking point, with many emphasizing its potential for long-term passive income. Despite some skepticism, community members express strong conviction in the project's potential and unique model.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network is trending as the community anticipates a major announcement and discusses potential partnerships, including speculation around Ripple and other institutional collaborations. Recent news highlights Zebec's advancements in real-time stablecoin payroll solutions and regulatory compliance, fueling optimism about its potential for growth and adoption. Some traders are focused on key support levels, while others are debating potential exchange listings and the timing of 

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

AIM ImmunoTech, Inc. (1100% jump in message volume)AIM ImmunoTech surged in retail discussions after announcing the first new subject was dosed in Phase 2 of its Phase 1b/2 trial for Ampligen and AstraZeneca’s (AZN) Imfinzi in late-stage pancreatic cancer treatment. Several Phase 1 patients who received the highest dose will also be included in Phase 2. The trial, known as DURIPANC, is taking place in the Netherlands and will enroll up to 25 patients in this phase.PepGen, Inc. (700% jump in message volume)PepGen shares and retail chatter <a href="https://stocktwits.com/news-articles/markets/equity/pepgen-stock-heads-for-best-week-since-sept-2022/chdghv2RyH">soared</a> after the company released early clinical data from its FREEDOM-DM1 Phase 1 trial for PGN-EDODM1 in myotonic dystrophy type 1 (DM1), a genetic disorder causing progressive muscle weakness. The company reported dose-dependent splicing correction of 12.3% at 5 mg/kg and 29.1% at 10 mg/kg at 28 days post-dosing.While single-dose studies haven’t shown functional improvements, PepGen sees early signs of benefits with repeat dosing. H.C. Wainwright called the data “very encouraging.”Aeon Biopharma, Inc. (700% jump in message volume)Aeon gained attention after announcing a 1-for-72 reverse stock split to meet NYSE American’s minimum share price requirement. The move took effect on Wednesday, with fractional shares rounded up.Last month, Aeon received a non-compliance notice from NYSE American for failing to meet the $2 million stockholders’ equity requirement. The company reported a $32.1 million stockholders’ deficit as of Sept. 30 and has suffered losses in its last two fiscal years. Aeon has until March 5 to submit a plan to regain compliance.Tiziana Life Sciences Ltd. (600% jump in message volume)Tiziana’s stock buzz jumped after a Nature Neuroscience study showed its nasal anti-CD3 monoclonal antibody significantly reduced neuroinflammation and improved recovery in a preclinical model of traumatic brain injury (TBI). The treatment correlated with less anxiety, reduced cognitive decline, and improved motor skills.Additionally, Tiziana revealed on Tuesday that its nasal anti-CD3 preclinical study is nearing completion and that foralumab could be a novel treatment for long COVID.Moleculin Biotech, Inc.&nbsp;(600% jump in message volume)Moleculin saw heightened retail discussion after announcing a $1.07 per share direct offering of about 3.3 million shares and warrants to an institutional investor, with 6.5 million warrants exercisable at $1.07 per share for five years.The company&nbsp;expected to close the offering on Feb. 26, with Roth Capital Partners as the placement agent. The company said proceeds would be used for working capital and general corporate purposes.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Hand holding test tube over stock data on computer monitor. | Image source: Getty Images

AIM ImmunoTech, PepGen, Aeon, Tiziana, Moleculin: 5 Biotech Stocks That Led Retail Message Growth Last Week

New trial data, a reverse split, and financing moves triggered a spike in retail chatter for these biotech stocks in the week ending Feb. 28, 2025.

Equity

New trial data, a reverse split, and financing moves triggered a spike in retail chatter for these biotech stocks in the week ending Feb. 28, 2025.


PepGen Inc. (PEPG) shares are on track for their best weekly performance since September 2022, surging 77% as retail interest skyrockets.&nbsp;The stock saw a 150% weekly spike in followers on Stocktwits, making it the fastest-growing biotech stock by retail engagement in this period.The rally follows PepGen's release of early clinical data from its FREEDOM-DM1 Phase 1 trial, evaluating PGN-EDODM1 in myotonic dystrophy type 1 (DM1) – a genetic disorder that causes progressive muscle weakness and wasting.The company reported dose-dependent splicing correction of 12.3% at 5 mg/kg and 29.1% at 10 mg/kg at 28 days post-dosing. While single-dose studies haven't shown functional improvements, PepGen sees early trends suggesting potential benefits with repeat dosing.The biotech firm expects results from the 15 mg/kg cohort in the second half of 2025 and from the FREEDOM2 5 mg/kg cohort in Q1 2026.H.C. Wainwright called the data "very encouraging," highlighting that the 29.1% splicing correction could have therapeutic significance, as all individuals in the study showed over 10% change in the splicing index.The research firm has a 'Buy' rating and a $16 price target.Stifel also noted a "highly promising signal on splicing" and saw an improved probability of success for PGN-EDODM1. The analyst called the results a "clear win" against low expectations, especially with PepGen trading below cash.On the financial side, PepGen reported a fourth-quarter loss of $0.68, better than an anticipated $0.72 loss. The company ended 2024 with $120.2 million in cash and equivalents, which it expects to fund operations into 2026.Some traders see PepGen as undervalued after its recent pullback, pointing to solid DM1 data and nearly $4 per share in cash.&nbsp;<stembedurl>https://stocktwits.com/BiotechValues/message/606027696</stembedurl>Another investor highlighted its strong cash position, no immediate financing risk, and promising trial results, arguing the selloff mid-week has made the stock's risk-reward profile more attractive.<stembedurl>https://stocktwits.com/BluntForceOptions/message/605835158</stembedurl>Short interest on <a href="https://stocktwits.com/symbol/PEPG">PepGen's stock</a> has edged down from 2.5% at the start of the year to 2.1% at the end of last week, according to Koyfin data.Shares of the company are down more than 84% in the past 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Short interest on PepGen's stock has edged down from 2.5% at the start of the year to 2.1% at the end of last week, according to Koyfin data. | Image source: Getty Images

PepGen Sees Fastest Weekly Retail Following Growth Among Biotech Stocks: What's Behind The Buzz?

The rally follows PepGen's release of early clinical data from its Phase 1 trial evaluating its therapy to treat a rare genetic disorder.

PepGen Reports Fourth Quarter and Year-End 2024 Financial Results and Recent Corporate Highlights

PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and...

PepGen Announces Positive Initial Results, Including Robust Splicing Correction, from Ongoing FREEDOM-DM1 Trial in Patients with DM1

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG...

PepGen Announces CONNECT Program Updates

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc...

PepGen Inc. develops oligonucleotide therapies. It is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics with the goal of transforming the treatment of severe neuromuscular and neurologic diseases. The company was founded in March 26, 2018 and is headquartered in Boston, MA.

PepGen Inc

$5,000

$6,000

$7,000

$8,000

What price will Ethereum hit in 2025? 
 
*Powered by Polymarket

PEPG
PepGen Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest PEPG News

PEPG PepGen Inc